Theravance Biopharma (TBPH) CFO Sawaf Aziz Sells Shares in Merger

What Happened

• Sawaf Aziz, Chief Financial Officer of Theravance Biopharma, reported dispositions of 204,966; 108,436; and 23,439 ordinary shares (total 336,841 shares) on September 23, 2026. The Form 4 lists these as dispositions to the issuer (cancellation under the merger), with per‑share price shown as N/A on the form.
• Under the Merger Agreement, each Theravance ordinary share was cancelled and converted into $17.00 in cash per share plus one contingent value right (CVR). The cash consideration for 336,841 shares equals approximately $5,726,297, and the reporting person also received non‑tradeable CVRs that pay only if specified commercial milestones are met. Some converted awards (RSUs/PSUs) were paid in cash and CVRs per the agreement.

Key Details

• Transaction date: September 23, 2026 (Effective Time of the merger); Form 4 filed September 24, 2026.
• Per‑share cash consideration (per Merger Agreement): $17.00; Form 4 shows price as N/A because shares were cancelled in the merger.
• Shares reported disposed: 204,966; 108,436; 23,439 (total 336,841). Approximate cash received: $5.73M before any applicable tax withholdings.
• Shares owned after transaction: Theravance ordinary shares held immediately prior to the Effective Time were cancelled — reporting person no longer holds Ordinary Shares; instead holds cash proceeds and CVRs (and any converted RSU/PSU cash rights).
• Notable footnotes: F1–F3 explain the merger conversion mechanics (ordinary shares, RSUs, and PSUs converted into cash + CVRs). CVRs are non‑tradeable contingent rights. Cash payments for converted awards are subject to any required tax withholding under the Merger Agreement.
• Timeliness: Filing appears timely (transaction 9/23/2026; Form 4 filed 9/24/2026).

Context

• This was not an open‑market sale but a merger cash‑out—routine corporate transaction where shares were cancelled per the acquisition terms. CVRs are contingent payments and are not freely tradable; they only pay out if defined milestones are achieved. As always, such merger conversions reflect deal terms rather than an insider signaling a view on the company’s future.